chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
A:Inhaled N-acetylcysteine 600 mg (300 twice a day)
B:Inhaled NS 6ml (3ml twice a day)
Sponsors
Affiliated Hospital of Chengdu University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients able to provide written informed consent and to fulfil study requests; 2. Outpatents, smoking or non-smoking, male or female; 3. Patients with a clinical diagnosis of COPD, post-bronchodilator FEV1/FVC <70%; 4. Diagnostic criteriameet the diagnostic criteria of Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease (Update 2014); 5. Patients with a history of at least two exacerbations within the previous two years and who are clinically stable for at least 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients with a diagnosis of bronchial asthma, cystic fibrosis, active pulmonary tuberculosis, pneumonia, bronchial pneumonia, bronchiectasis, lung cancer or lung metastases, other progressively fatal disease; 2. Patients with severe cardiovascular diseases, severe neurological diseases or severely impaired hepatic or renal function; 3. Patients taken inhaled corticosteroids or oral corticosteroids in the previous 1 month before hospitality entry; 4. Patients with any types of infection in precious 2 weeks; 5. Be allergy to study medications (N-acetylcysteine, NAC); 6. with reading or communication disorders; 7. Unsuitable for the study for every other reasons, in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ros, Rp, Rc test by IOS;MDA, SOD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay (LOS);modified medical british research council, mMRC score;SGRQ scale score;PCT, hs-CRP, IL-6, IL-8; | — |
Countries
China
Contacts
Public ContactZhou Hui
Outcome results
None listed